[go: up one dir, main page]

WO1988006440A3 - Nystatine a liposome incorpore - Google Patents

Nystatine a liposome incorpore Download PDF

Info

Publication number
WO1988006440A3
WO1988006440A3 PCT/US1988/000632 US8800632W WO8806440A3 WO 1988006440 A3 WO1988006440 A3 WO 1988006440A3 US 8800632 W US8800632 W US 8800632W WO 8806440 A3 WO8806440 A3 WO 8806440A3
Authority
WO
WIPO (PCT)
Prior art keywords
nystatin
liposome
incorporated
agent
lipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/000632
Other languages
English (en)
Other versions
WO1988006440A2 (fr
Inventor
Gabriel Lopez-Berestein
Reeta Mehta
Roy L Hofper
Rudolph L Juliano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to AT88903033T priority Critical patent/ATE79028T1/de
Priority to DE8888903033T priority patent/DE3873528T2/de
Publication of WO1988006440A2 publication Critical patent/WO1988006440A2/fr
Publication of WO1988006440A3 publication Critical patent/WO1988006440A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agent liposomique destiné au traitement d'infections mycosiques disséminées chez l'animal, comprenant de la nystatine et des lipides.
PCT/US1988/000632 1987-03-03 1988-03-02 Nystatine a liposome incorpore Ceased WO1988006440A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT88903033T ATE79028T1 (de) 1987-03-03 1988-03-02 Nystatin enthaltende liposome.
DE8888903033T DE3873528T2 (de) 1987-03-03 1988-03-02 Nystatin enthaltende liposome.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/021,367 US4812312A (en) 1987-03-03 1987-03-03 Liposome-incorporated nystatin
US021,367 1993-02-23

Publications (2)

Publication Number Publication Date
WO1988006440A2 WO1988006440A2 (fr) 1988-09-07
WO1988006440A3 true WO1988006440A3 (fr) 1988-10-20

Family

ID=21803795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/000632 Ceased WO1988006440A2 (fr) 1987-03-03 1988-03-02 Nystatine a liposome incorpore

Country Status (7)

Country Link
US (1) US4812312A (fr)
EP (1) EP0348431B1 (fr)
JP (1) JP2703594B2 (fr)
AT (1) ATE79028T1 (fr)
AU (1) AU1491788A (fr)
DE (1) DE3873528T2 (fr)
WO (1) WO1988006440A2 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5830498A (en) * 1987-10-16 1998-11-03 Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4981690A (en) * 1987-10-27 1991-01-01 Board Of Regents, The University Of Texas System Liposome-incorporated mepartricin
JPH03502327A (ja) * 1988-01-19 1991-05-30 ボード・オブ・リージェンツ，ザ・ユニバーシティ・オブ・テキサス・システム ３’‐デアミノドキソルビシンのエステル体、そのリポソーム組成物およびその使用方法
US4999199A (en) * 1988-11-10 1991-03-12 Board Of Regents, The University Of Texas System Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
US5077057A (en) * 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ATE137403T1 (de) * 1989-03-31 1996-05-15 Univ California Zubereitung von liposomen- und lipid- komplexzusammensetzungen
US5277914A (en) * 1989-03-31 1994-01-11 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
AU6428890A (en) * 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
IT1240354B (it) * 1990-03-30 1993-12-07 Poli Ind Chimica Spa Formulazioni liposomiali di farmaci antimicotici,antibatterici e/o antantiflogistici per applicazione locale e vaginale
US5670350A (en) * 1990-08-20 1997-09-23 Novartis Finance Corporation Genomic DNA encoding a pseudomonas global transcriptional activation element and its use in activating gene expression
US5662898A (en) * 1990-08-20 1997-09-02 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
CA2099772A1 (fr) * 1991-01-14 1992-07-15 Gabriel Lopez-Berestein Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih
US5683714A (en) * 1991-04-19 1997-11-04 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin pharmaceutical formulation
US5270052A (en) * 1991-04-19 1993-12-14 New England Medical Center Hospitals, Inc. Methods and compositions for treatment of infection by intracellular parasites
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
JPH08503966A (ja) * 1993-09-29 1996-04-30 ギスト ブロカデス ナムローゼ フェンノートシャップ 新規な抗真菌性組成物
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5693336A (en) * 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
WO1998033482A1 (fr) * 1997-02-04 1998-08-06 Abbott Laboratories Formulation analgesique a administration parenterale encapsulee dans un liposome
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
MXPA03004095A (es) * 2000-11-09 2004-09-10 Neopharm Inc Complejos de sn-38 con lipidos y sus metodos de uso.
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (fr) * 2002-08-20 2004-04-29 Neopharm, Inc. Formulation de sn-38 a base de lipides pharmaceutiquement actifs
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
EP1874793A4 (fr) 2005-04-15 2008-12-24 Univ Texas Administration d'arnsi par compositions lipidiques neutres
US9393198B2 (en) * 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
WO2012167212A2 (fr) 2011-06-03 2012-12-06 Signpath Pharma Inc. Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
CA2882978A1 (fr) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumine-er, nanocurcumine liposomale a liberation prolongee-plga pour reduire au minimum la prolongation du qt dans les therapies anticancereuses
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
EP3448374B1 (fr) 2016-04-27 2025-02-12 Signpath Pharma Inc. Prévention d'un bloc atrio-ventriculaire induit par des médicaments
EP3538106A4 (fr) * 2016-11-09 2021-03-24 Signpath Pharma, Inc. Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des médicaments provoquant des canalopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001933A1 (fr) * 1985-09-27 1987-04-09 Liposome Technology, Inc. Composition stabilisee de liposomes/amphotericines et procede

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
JPS5622724A (en) * 1979-08-02 1981-03-03 Asahi Chem Ind Co Ltd Pharmaceutical preparation of n4-acylcytosine arabinoside
JPS59500952A (ja) * 1982-03-29 1984-05-31 ザ　リポソ−ム　カンパニ−、インコ−ポレ−テッド 安定なプルリラメラベシクル類
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001933A1 (fr) * 1985-09-27 1987-04-09 Liposome Technology, Inc. Composition stabilisee de liposomes/amphotericines et procede

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 83, no. 9, 1 September 1975, (Columbus, Ohio, US), B.E. Cohen: "Permeability of liposomes to nonelectrolytes. II. Effect of nystatin and gramicidin A.", see page 267 *
Chemical Abstracts, volume 91, no. 15, 8 October 1979, (Columbus, Ohio, US), Z. Iqbal et al.: "Pre-resonance Raman spectra and conformations of nystatin in powder, solution and phospholipid-cholesterol multi-layers", see page 213 *

Also Published As

Publication number Publication date
DE3873528D1 (de) 1992-09-10
DE3873528T2 (de) 1993-01-21
WO1988006440A2 (fr) 1988-09-07
JPH02502459A (ja) 1990-08-09
JP2703594B2 (ja) 1998-01-26
ATE79028T1 (de) 1992-08-15
EP0348431B1 (fr) 1992-08-05
AU1491788A (en) 1988-09-26
US4812312A (en) 1989-03-14
EP0348431A1 (fr) 1990-01-03

Similar Documents

Publication Publication Date Title
WO1988006440A3 (fr) Nystatine a liposome incorpore
USD387168S (en) Control station
HU894025D0 (en) Herbicide preparatives and process for producing alkoxy- -1,2,4-triazolo(1,5-c)pyrimidine-2-sulfonamides utilized as active substance
USD262804S (en) Lottery die
EP0690039A3 (fr) Alcools et acides substitués avec des groupes poly-perfluoroalkyles, et leurs dérivés
EG18726A (en) 1-Nitro-2,2 diaminoethylene derivatives and their use in pest control.
EP0196334A4 (fr) Procede de destruction de cellules et agent destructeur de cellules.
AU6704890A (en) 4-phosphonomethyl-2-hydroxy-2-oxo-1,4,2-oxazaphosphorinane n-oxide and water-soluble salts therof
AU1286988A (en) Oil-in-water emulsions, a process for their preparation and their use
AU3592897A (en) Toxins active against pests
AU8093487A (en) Improvement in bromphenriamine, pseudoephedrine therapy
AU7573087A (en) Substituted hydrazones, process for the preparation and their use as pesticide
NL980042I1 (nl) Plaatselijke formuleringen en transdermale afleversystemen die 1-isobutyl-1H-imidazoc4,5-c!chinolin-4-amine bevatten.
HUT44414A (en) Pesticide comprising 1,2,3,6 tetrahydro-5-nitropyrimidine derivatives as active substance and process for preparing the active substance
AU2578488A (en) A product, cosmetic sunscreen product, and a method for introducing an active substance into the skin
TR199500944A1 (tr) Bir emniyet ürünü, bir film ve bir emniyet ürününün imali icin bir yöntem.
NO881386D0 (no) Forstoff, samt fremstilling derav.
NO880306L (no) Bindemiddel, samt fremstilling derav.
AU7738287A (en) 1-substituted aryl-3-tert. butyl-pyrazoles
USD264249S (en) Ear plug
DE3862490D1 (de) Mittel zur insekten- und milbenabwehr.
AU7203987A (en) Multistage finishing device and method
USD267074S (en) Log lifter
GB9415465D0 (en) An improvement in dry shaving devices, known as the rotarazor
USD275258S (en) Emergency entrance tool

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1988903033

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1988903033

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988903033

Country of ref document: EP